Chemotherapy Drug Assessment
Chemotherapy Drug Assessment - Related Videos
07:42
Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
0 Views •
Cited by 28 •
2012
This abstract describes a novel method to assess the development of neurotoxicity in patients receiving chemotherapy treatment. While conventional assessment methods are limited in their ability to detect early changes in nerve function, nerve excitability techniques provide early identification of patients at risk of severe neurotoxicity and insight into pathophysiology.
08:41
Modeling Chemotherapy Resistant Leukemia In Vitro
0 Views •
Cited by 15 •
2016
The current report summarizes a protocol that can be utilized to model the influence of the bone marrow microenvironment niche on leukemic cells with emphasis placed on enrichment of the most chemoresistant subpopulation.
09:39
Assessing Specificity of Anticancer Drugs In Vitro
0 Views •
Cited by 8 •
2016
The goal of this protocol is to assess specificity of anticancer drugs in vitro using mixed cultures containing both tumor and non-tumor cells.
09:25
Assessment of Ultrasonic Vocalizations During Drug Self-administration in Rats
0 Views •
Cited by 17 •
2010
Drug self-administration and ultrasonic vocalizations (USV) are used as behavioral assessments in animal research, but rarely in combination. The purpose of this article is to describe the advantages of recording USVs during drug self-administration procedures to assess affective responses to drug experience.
13:17
The Mesenteric Lymph Duct Cannulated Rat Model: Application to the Assessment of Intestinal Lymphatic Drug Transport
0 Views •
Cited by 48 •
2015
Here we describe a technique to cannulate the mesenteric lymph duct in rats which enables quantification of lipid and drug transport via the lymphatic system following intestinal delivery. The technique can be adapted to assess mesenteric lymph concentrations and/or transport of fluid, immune cells, peptides, proteins and lipophilic molecules.
FAQs
Dose-response analysis shows how changes in drug concentration alter tumor-cell outcomes. Investigators can compare concentrations with corresponding effects on viability, proliferation, or apoptosis, revealing whether responses increase, decrease, or vary across tested conditions. This relationship helps distinguish weak activity from a reproducible treatment effect and supports comparison of candidate compounds during further development.
These measurements describe different aspects of treatment response. Cell viability indicates whether tumor cells remain alive, whereas proliferation shows whether surviving cells continue to expand. Apoptosis provides evidence of programmed cell death as a response outcome. Considering these measures together can clarify how strongly a compound affects tumor cells and can contribute to understanding its potential mechanism of action.
Changes in response across tested tumor cells or model systems can reveal resistance patterns, including situations in which a candidate produces limited effects. These findings help investigators compare treatment sensitivity and identify questions for combination-treatment studies. Assessment therefore supports not only selection of active compounds, but also exploration of strategies intended to improve responses when one drug alone is insufficient.
A typical assessment exposes tumor cells or another defined model system to selected drug concentrations, then measures outcomes such as viability, proliferation, or apoptosis. Investigators may also examine effects in noncancerous cells to evaluate toxicity. Comparing these results across concentrations and model types produces evidence about response strength, selectivity, and whether a candidate merits additional study.
Testing noncancerous cells provides a comparison for effects observed in tumor cells. A compound may reduce tumor-cell viability or proliferation while also harming noncancerous cells, so both responses are relevant when evaluating treatment selectivity. This comparison helps investigators assess whether anticancer activity is accompanied by harmful effects on healthy cell models and informs decisions about further development.
The approach is useful when investigators need to compare anticancer candidates, optimize treatment choices, or determine whether a compound warrants further development or clinical consideration. Results can support dose-response analysis, evaluation of treatment selectivity, investigation of resistance, and planning of combination-treatment studies. Together, these findings provide experimental evidence for prioritizing therapies with promising activity and manageable toxicity profiles.